Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 4.5% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price rose 4.5% during trading on Monday . The company traded as high as $6.68 and last traded at $6.64. Approximately 6,581,735 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 10,331,976 shares. The stock had previously closed at $6.35.

Analysts Set New Price Targets

RXRX has been the topic of a number of recent analyst reports. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Leerink Partners cut their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Up 7.2 %

The firm has a 50 day moving average price of $7.54 and a 200-day moving average price of $7.02. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.42) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Integrated Advisors Network LLC increased its holdings in Recursion Pharmaceuticals by 36.8% in the fourth quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company’s stock valued at $119,000 after purchasing an additional 4,731 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $54,000. CSS LLC IL acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Recursion Pharmaceuticals by 5.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company’s stock worth $15,272,000 after purchasing an additional 118,428 shares during the period. Finally, Vident Advisory LLC acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $80,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.